This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
asthma exacerbations | 644 |
lung function | 567 |
allergic rhinitis | 483 |
respiratory tract | 404 |
severe asthma | 376 |
epithelial cells | 359 |
specific ige | 339 |
asthma control | 336 |
airway inflammation | 327 |
asthma exacerbation | 302 |
viral infections | 287 |
respiratory syncytial | 264 |
syncytial virus | 259 |
childhood asthma | 238 |
asthma symptoms | 236 |
viral infection | 228 |
food allergy | 220 |
lung cancer | 214 |
respiratory viruses | 210 |
lung disease | 204 |
acute asthma | 204 |
immune response | 203 |
pulmonary disease | 201 |
atopic dermatitis | 198 |
air pollution | 197 |
risk factors | 195 |
asthmatic patients | 190 |
lower respiratory | 185 |
chronic obstructive | 181 |
control group | 181 |
skin prick | 178 |
obstructive pulmonary | 173 |
increased risk | 172 |
asthma patients | 172 |
induced asthma | 167 |
respiratory infections | 167 |
smooth muscle | 160 |
dust mite | 156 |
united states | 156 |
allergic asthma | 155 |
mean age | 152 |
pulmonary function | 150 |
respiratory symptoms | 150 |
allergic diseases | 148 |
risk factor | 148 |
house dust | 147 |
asthmatic children | 145 |
airway epithelial | 144 |
systematic review | 144 |
inhaled corticosteroids | 143 |
nitric oxide | 143 |
controlled trial | 140 |
peripheral blood | 140 |
cohort study | 138 |
asthma severity | 137 |
respiratory disease | 137 |
young children | 135 |
ige levels | 133 |
mast cells | 131 |
early life | 129 |
allergic disease | 127 |
years old | 127 |
airway obstruction | 126 |
upper respiratory | 125 |
total ige | 125 |
grass pollen | 124 |
persistent asthma | 123 |
age years | 122 |
respiratory viral | 122 |
acute respiratory | 122 |
bone marrow | 121 |
tract infections | 121 |
cystic fibrosis | 119 |
bronchial asthma | 116 |
significantly higher | 116 |
case report | 115 |
may also | 115 |
immune system | 110 |
bronchial epithelial | 109 |
virus infection | 107 |
dendritic cells | 106 |
nasal polyps | 106 |
statistically significant | 105 |
allergic patients | 104 |
prick test | 103 |
growth factor | 103 |
health care | 103 |
asthmatic subjects | 102 |
tract infection | 101 |
exhaled nitric | 101 |
cd cd | 100 |
airway hyperresponsiveness | 99 |
air quality | 99 |
early childhood | 96 |
family history | 96 |
viral respiratory | 96 |
immune responses | 96 |
rhinovirus infection | 95 |
airway epithelium | 93 |
side effects | 93 |
pregnant women | 93 |
airflow obstruction | 91 |
adverse events | 90 |
significant difference | 89 |
common cold | 89 |
prick tests | 88 |
da asma | 88 |
first year | 86 |
mast cell | 86 |
current asthma | 86 |
emergency department | 85 |
year old | 84 |
peak flow | 84 |
clinical trials | 83 |
pulmonary fibrosis | 82 |
otitis media | 81 |
mg ml | 81 |
clinical trial | 81 |
airway disease | 80 |
data suggest | 80 |
chronic respiratory | 80 |
allergic sensitization | 80 |
skin tests | 80 |
human metapneumovirus | 80 |
airway smooth | 79 |
skin test | 79 |
clinical practice | 79 |
airway remodeling | 79 |
und die | 79 |
respiratory virus | 78 |
randomized controlled | 78 |
prospective study | 78 |
influenza virus | 77 |
children aged | 77 |
gene expression | 77 |
primary care | 76 |
doc id | 76 |
respiratory health | 76 |
preschool children | 76 |
inflammatory response | 76 |
cord uid | 76 |
recurrent wheezing | 75 |
respiratory diseases | 75 |
high risk | 75 |
expiratory flow | 75 |
respiratory infection | 74 |
environmental factors | 74 |
flow cytometry | 74 |
serum ige | 73 |
eosinophilic inflammation | 73 |
asthma attacks | 73 |
important role | 72 |
inflammatory cytokines | 72 |
bronchoalveolar lavage | 71 |
birth cohort | 71 |
asthma development | 71 |
least one | 71 |
innate immune | 70 |
allergic reactions | 70 |
acute exacerbations | 70 |
chronic asthma | 69 |
ng ml | 69 |
human rhinovirus | 69 |
high levels | 69 |
pg ml | 68 |
allergic inflammation | 68 |
healthy controls | 68 |
asm cells | 68 |
diagnosed asthma | 67 |
epithelial cell | 67 |
control subjects | 67 |
significant differences | 67 |
nasal spray | 66 |
rv infection | 66 |
respiratory illness | 66 |
lung diseases | 66 |
asthma management | 65 |
mrna expression | 65 |
among children | 65 |
mg dl | 65 |
disease severity | 64 |
recent studies | 64 |
lung tissue | 64 |
cigarette smoke | 64 |
inflammatory cells | 64 |
one study | 64 |
natural history | 64 |
recent study | 64 |
dust mites | 63 |
peak expiratory | 63 |
copd patients | 63 |
allergen exposure | 63 |
lower airway | 62 |
mg kg | 62 |
respiratory system | 62 |
skin testing | 62 |
two groups | 62 |
induced sputum | 62 |
rsv infection | 61 |
well tolerated | 61 |
significantly increased | 61 |
tobacco smoke | 61 |
old children | 60 |
iu ml | 60 |
mouse model | 60 |
fev fvc | 60 |
older adults | 60 |
severe ea | 60 |
adverse effects | 60 |
first years | 60 |
bronchial hyperresponsiveness | 60 |
hygiene hypothesis | 60 |
forced expiratory | 60 |
interstitial lung | 59 |
oxidative stress | 59 |
without asthma | 58 |
asthma prevalence | 58 |
eosinophil counts | 58 |
informed consent | 58 |
uncontrolled asthma | 58 |
medication use | 58 |
food allergens | 57 |
inhaled corticosteroid | 57 |
cytokine production | 57 |
may contribute | 57 |
infl uenza | 57 |
clinical symptoms | 57 |
age group | 57 |
allergic airway | 56 |
elderly patients | 56 |
asthma bronchiale | 56 |
general population | 55 |
monoclonal antibody | 55 |
positive skin | 55 |
respiratory distress | 55 |
asthma medication | 54 |
one year | 54 |
th cells | 54 |
eosinophilic esophagitis | 54 |
allergen challenge | 54 |
seasonal allergic | 54 |
commonly used | 53 |
bei der | 53 |
function testing | 53 |
upper airway | 53 |
adult patients | 53 |
measured using | 53 |
indoor air | 53 |
asthma phenotypes | 53 |
auf die | 53 |
also found | 52 |
controlled trials | 52 |
serum levels | 52 |
feno levels | 51 |
airway responsiveness | 51 |
mechanical ventilation | 51 |
logistic regression | 51 |
eosinophil count | 51 |
public health | 51 |
hospital admissions | 51 |
old male | 51 |
significant increase | 50 |
another study | 50 |
controlled asthma | 50 |
higher risk | 50 |
atopic asthma | 50 |
one patient | 49 |
chronic rhinosinusitis | 49 |
type i | 49 |
nasal congestion | 49 |
respiratory pathogens | 49 |
lower airways | 49 |
chronic inflammatory | 48 |
asthma treatment | 48 |
obstructive sleep | 48 |
acute exacerbation | 48 |
patients treated | 48 |
airway resistance | 48 |
respiratory illnesses | 48 |
mg day | 48 |
thoracic society | 48 |
specific immunotherapy | 47 |
specific igg | 47 |
per year | 47 |
significantly reduced | 47 |
symptom score | 47 |
control study | 46 |
general practice | 46 |
food allergies | 46 |
weight loss | 46 |
performed using | 46 |
chest tightness | 46 |
increased airway | 46 |
chronic lung | 46 |
long term | 46 |
idiopathic pulmonary | 46 |
human bocavirus | 46 |
study showed | 46 |
nasal polyposis | 46 |
function tests | 45 |
hypersensitivity reactions | 45 |
chronic urticaria | 45 |
pilot study | 45 |
peanut allergy | 45 |
like receptor | 45 |
asthma outcomes | 45 |
study group | 45 |
pediatric asthma | 45 |
pollen season | 45 |
significantly associated | 44 |
sleep apnea | 44 |
median age | 44 |
innate immunity | 44 |
systemic corticosteroids | 44 |
fatty acids | 44 |
tidal breathing | 44 |
air pollutants | 44 |
asthma diagnosis | 44 |
significant improvement | 44 |
several studies | 44 |
clinical characteristics | 43 |
abdominal pain | 43 |
stable asthma | 43 |
rsv bronchiolitis | 43 |
blood eosinophil | 43 |
year follow | 43 |
induced wheezing | 43 |
allergic symptoms | 43 |
im rahmen | 42 |
onset asthma | 42 |
poor asthma | 42 |
mild asthma | 42 |
adhesion molecule | 42 |
acting beta | 42 |
ige level | 41 |
aber auch | 41 |
adrenergic receptor | 41 |
united kingdom | 41 |
thymic stromal | 41 |
may lead | 41 |
chlamydia pneumoniae | 41 |
ocs dose | 41 |
birth weight | 41 |
stromal lymphopoietin | 41 |
nasal symptoms | 41 |
hay fever | 41 |
leukotriene receptor | 40 |
significantly lower | 40 |
neutrophilic inflammation | 40 |
basic protein | 40 |
auch die | 40 |
immune cells | 40 |
controlled study | 40 |
severe disease | 40 |
may result | 40 |
equine asthma | 40 |
th response | 39 |
asthma may | 39 |
animal models | 39 |
milk allergy | 39 |
respiratory failure | 39 |
pulmonary hypertension | 39 |
eosinophilic asthma | 39 |
asthma education | 39 |
clinical presentation | 39 |
results suggest | 39 |
mycoplasma pneumoniae | 39 |
two years | 39 |
developing asthma | 39 |
provocation test | 39 |
physical examination | 39 |
allergic reaction | 39 |
respiratory function | 39 |
world health | 39 |
oral corticosteroids | 39 |
cell lines | 39 |
expiratory volume | 39 |
induced airway | 39 |
asthma pathogenesis | 39 |
influenza vaccination | 38 |
airway hyper | 38 |
atopic disease | 38 |
clinical features | 38 |
airflow limitation | 38 |
sectional study | 38 |
old female | 38 |
extracellular matrix | 38 |
disordered breathing | 37 |
wheezing episodes | 37 |
nasal mucosa | 37 |
adult asthma | 37 |
necrosis factor | 37 |
including asthma | 37 |
patients received | 37 |
hong kong | 37 |
major basic | 37 |
pediatric patients | 37 |
severe exacerbations | 37 |
intensive care | 37 |
old woman | 37 |
allergic rhinoconjunctivitis | 37 |
th cytokines | 37 |
osa patients | 37 |
airway remodelling | 37 |
odds ratio | 37 |
placebo group | 37 |
inflammatory mediators | 37 |
growth factors | 37 |
ventilation heterogeneity | 37 |
hypereosinophilic syndrome | 36 |
pinto mendes | 36 |
disease control | 36 |
polymerase chain | 36 |
previous studies | 36 |
guinea pigs | 36 |
chain reaction | 36 |
antibiotic use | 36 |
airway diseases | 36 |
mononuclear cells | 36 |
severe persistent | 36 |
budesonide formoterol | 36 |
allergic subjects | 36 |
treatment group | 36 |
may occur | 36 |
significant reduction | 36 |
aged years | 36 |
experimental rhinovirus | 36 |
may play | 36 |
fev predicted | 36 |
chronic disease | 36 |
building syndrome | 36 |
national health | 36 |
healthy individuals | 36 |
studies suggest | 35 |
sbs symptoms | 35 |
inhaled steroids | 35 |
many patients | 35 |
distress syndrome | 35 |
particulate matter | 35 |
birch pollen | 35 |
human eosinophils | 35 |
positive correlation | 35 |
sick building | 35 |
medical history | 35 |
age groups | 35 |
symptom scores | 35 |
acute wheezing | 35 |
hospital admission | 35 |
children hospitalized | 35 |
amino acid | 34 |
chronic inflammation | 34 |
bacterial infections | 34 |
transforming growth | 34 |
virus bronchiolitis | 34 |
moderate asthma | 34 |
copd subjects | 34 |
oral steroids | 34 |
inflammatory diseases | 34 |
sublingual immunotherapy | 34 |
clinical outcomes | 34 |
action plan | 34 |
increased levels | 34 |
ige binding | 34 |
higher levels | 34 |
receptor antagonists | 34 |
randomised controlled | 34 |
outdoor air | 34 |
infectious diseases | 34 |
acute bronchitis | 33 |
global initiative | 33 |
recent years | 33 |
allergen immunotherapy | 33 |
occupational asthma | 33 |
protein levels | 33 |
observational study | 33 |
bronchopulmonary dysplasia | 33 |
test results | 33 |
longitudinal study | 33 |
factors associated | 33 |
primary outcome | 33 |
may help | 33 |
ige antibodies | 33 |
eosinophilic infiltration | 33 |
retrospective study | 33 |
regression analysis | 33 |
fi rst | 33 |
blood eosinophilia | 33 |
allergic response | 32 |
human airway | 32 |
twice daily | 32 |
among patients | 32 |
fluticasone propionate | 32 |
high prevalence | 32 |
egg white | 32 |
lung volumes | 32 |
determine whether | 32 |
two patients | 32 |
inclusion criteria | 32 |
receptor antagonist | 32 |
mild persistent | 32 |
clinically relevant | 32 |
epidemiological studies | 32 |
smoke exposure | 32 |
blood eosinophils | 32 |
health effects | 32 |
asthma medications | 32 |
findings suggest | 32 |
chronic cough | 32 |
eosinophil infiltration | 32 |
like symptoms | 32 |
muc ac | 32 |
cd cells | 32 |
exhaled breath | 32 |
severe allergic | 32 |
literature review | 32 |
bronchial epithelium | 32 |
drug allergy | 32 |
healthy children | 31 |
common cause | 31 |
heart rate | 31 |
collagen iv | 31 |
asthmatic individuals | 31 |
proinflammatory cytokines | 31 |
health organization | 31 |
cationic protein | 31 |
th cytokine | 31 |
und der | 31 |
asthma risk | 31 |
fatty acid | 31 |
sputum eosinophils | 31 |
airway eosinophilia | 31 |
endotoxin levels | 31 |
young adults | 31 |
blood mononuclear | 31 |
vital capacity | 31 |
cohort studies | 31 |
lung volume | 31 |
school children | 31 |
cancer cells | 31 |
phase ii | 31 |
mass spectrometry | 31 |
combination therapy | 31 |
bronchial hyperreactivity | 31 |
refractory asthma | 30 |
nasal polyp | 30 |
hearing loss | 30 |
candidate genes | 30 |
igg levels | 30 |
also known | 30 |
asthma therapy | 30 |
cell responses | 30 |
normal subjects | 30 |
airway hyperreactivity | 30 |
mass index | 30 |
protective effect | 30 |
clinical course | 30 |
body mass | 30 |
health outcomes | 30 |
see table | 30 |
gastroesophageal reflux | 30 |
fold increase | 30 |
randomized trial | 30 |
respiratory rate | 30 |
corticosteroid treatment | 30 |
environmental exposures | 30 |
eosinophil cationic | 30 |
ics laba | 30 |
airway wall | 30 |
eosinophil recruitment | 30 |
total protein | 29 |
mite allergen | 29 |
rhinovirus infections | 29 |
clinical manifestations | 29 |
treatment groups | 29 |
risk children | 29 |
forced oscillation | 29 |
healthy subjects | 29 |
inflammatory cell | 29 |
differential diagnosis | 29 |
nitrogen dioxide | 29 |
study aimed | 29 |
basement membrane | 29 |
poorly controlled | 29 |
clinical efficacy | 29 |
ist die | 29 |
phase iii | 29 |
patients may | 29 |
tumor necrosis | 29 |
safety profile | 29 |
ct scan | 29 |
pollen allergy | 29 |
barrier function | 29 |
chart review | 29 |
consecutive patients | 29 |
asthma morbidity | 29 |
skeletal muscle | 29 |
prospective cohort | 29 |
low birth | 29 |
significantly decreased | 29 |
allergen sensitization | 28 |
asm cell | 28 |
th th | 28 |
endotoxin exposure | 28 |
bal fluid | 28 |
aspergillus fumigatus | 28 |
asthma action | 28 |
last months | 28 |
cell counts | 28 |
patients without | 28 |
significantly greater | 28 |
goblet cell | 28 |
primary prevention | 28 |
cell activation | 28 |
requiring hospitalization | 28 |
care unit | 28 |
lavage fluid | 28 |
asthmatic airways | 28 |
phagocytic ability | 28 |
oscillation technique | 28 |
eosinophilic myositis | 28 |
genome load | 28 |
clinical studies | 28 |
present study | 28 |
influenza vaccine | 28 |
sputum samples | 27 |
high doses | 27 |
inhaled steroid | 27 |
chronic airway | 27 |
clinically significant | 27 |
rhinovirus genome | 27 |
nocturnal enuresis | 27 |
also associated | 27 |
study found | 27 |
helper type | 27 |
als auch | 27 |
inflammatory responses | 27 |
mit der | 27 |
allergischer erkrankungen | 27 |
viral replication | 27 |
even though | 27 |
family members | 27 |
nasal aspirates | 27 |
tree nut | 27 |
structural changes | 27 |
virus infections | 27 |
celiac disease | 27 |
adverse reactions | 27 |
asthma group | 27 |
reflux disease | 27 |
mit einer | 27 |
inflammatory airway | 27 |
chronic bronchitis | 27 |
cells mm | 27 |
last years | 27 |
hrv infection | 27 |
breath condensate | 27 |
last year | 27 |
sensitive asthma | 27 |
american thoracic | 27 |
alveolar macrophages | 27 |
epithelial barrier | 27 |
diagnostic criteria | 27 |
widely used | 27 |
airway function | 27 |
cysteinyl leukotrienes | 26 |
heart disease | 26 |
per person | 26 |
within minutes | 26 |
previously reported | 26 |
leading cause | 26 |
two different | 26 |
atopic diseases | 26 |
office buildings | 26 |
bacterial infection | 26 |
increased prevalence | 26 |
cell count | 26 |
tidal volume | 26 |
reported asthma | 26 |
cat allergen | 26 |
wheezing illness | 26 |
sample size | 26 |
cancer cell | 26 |
much higher | 26 |
significantly improved | 26 |
blood pressure | 26 |
cord blood | 26 |
previous months | 26 |
reduced lung | 26 |
blood flow | 26 |
eosinophils may | 26 |
cell differentiation | 26 |
low dose | 26 |
innate lymphoid | 26 |
first time | 26 |
clinical history | 26 |
recurrent airway | 26 |
cell line | 26 |
effective treatment | 26 |
connective tissue | 26 |
clinical improvement | 26 |
asthma care | 26 |
patients aged | 26 |
per week | 26 |
environmental tobacco | 26 |
taken together | 26 |
systemic inflammation | 26 |
better understanding | 26 |
clinical assessment | 26 |
control groups | 26 |
potential role | 26 |
acquired pneumonia | 25 |
intervention group | 25 |
based study | 25 |
statistical analysis | 25 |
cells may | 25 |
also showed | 25 |
granule proteins | 25 |
pulmonary artery | 25 |
within hours | 25 |
studies showed | 25 |
patch test | 25 |
ex vivo | 25 |
heart failure | 25 |
gold standard | 25 |
ipratropium bromide | 25 |
wheezing episode | 25 |
major allergen | 25 |
elevated levels | 25 |
wide range | 25 |
allergen avoidance | 25 |
preterm infants | 25 |
treatment period | 25 |
community study | 25 |
significant correlation | 25 |
significant decrease | 25 |
serum periostin | 25 |
severe respiratory | 25 |
sputum eosinophilia | 25 |
international study | 25 |
lung transplantation | 25 |
allergic conjunctivitis | 25 |
zu einer | 25 |
asthma among | 25 |
may cause | 25 |
challenge test | 25 |
clinical relevance | 25 |
many studies | 25 |
blood samples | 25 |
immune function | 25 |
severe acute | 25 |
emergency room | 25 |
airway pressure | 25 |
health study | 25 |
epidemiologic studies | 25 |
hypertonic saline | 25 |
ige mediated | 24 |
rhinovirus illnesses | 24 |
airways disease | 24 |
contact dermatitis | 24 |
clinically diagnosed | 24 |
gastrointestinal tract | 24 |
bronchodilator response | 24 |
high dose | 24 |
significantly different | 24 |
fvc ratio | 24 |
mc sn | 24 |
urgent hcu | 24 |
may reduce | 24 |
da resposta | 24 |
study population | 24 |
bronchial mucosa | 24 |
fungal sensitization | 24 |
moderate ea | 24 |
allergic bronchopulmonary | 24 |
subsequent development | 24 |
azelastine nasal | 24 |
serum total | 24 |
prospective studies | 24 |
natural killer | 24 |
asthma candidate | 24 |
atopic eczema | 24 |
past months | 24 |
tree pollen | 24 |
cell types | 24 |
first months | 24 |
microbial products | 24 |
blood cells | 24 |
national asthma | 24 |
six months | 24 |
indoor environment | 24 |
asthma phenotype | 24 |
evidence suggests | 24 |
obstructive lung | 24 |
parainfluenza virus | 24 |
university hospital | 24 |
asthma guidelines | 24 |
control medication | 24 |
multiplex pcr | 24 |
strongly associated | 24 |
higher prevalence | 24 |
port hedland | 24 |
hospitalized children | 24 |
one week | 24 |
time pcr | 24 |
des arg | 24 |
control test | 24 |
rhinitis symptoms | 24 |
food challenge | 23 |
anaphylactic reaction | 23 |
dermatophagoides pteronyssinus | 23 |
ige reactivity | 23 |
year history | 23 |
determined using | 23 |
atopic status | 23 |
tract symptoms | 23 |
control measures | 23 |
large number | 23 |
older people | 23 |
clinical diagnosis | 23 |
systemic steroids | 23 |
histamine release | 23 |
lung inflammation | 23 |
sputum eosinophil | 23 |
preterm birth | 23 |
treated patients | 23 |
asthma hospitalizations | 23 |
clinical response | 23 |
candidate gene | 23 |
volatile organic | 23 |
hypersensitivity reaction | 23 |
maintenance dose | 23 |
lower levels | 23 |
detection rate | 23 |
inhalant allergens | 23 |
cell proliferation | 23 |
viral bronchiolitis | 23 |
recurrent infections | 23 |
acute viral | 23 |
cell apoptosis | 23 |
patients receiving | 23 |
allergic children | 23 |
tissue eosinophilia | 23 |
less likely | 23 |
adaptive immune | 23 |
hemmung der | 23 |
chronic sinusitis | 23 |
age range | 23 |
sleep disordered | 23 |
gold stage | 23 |
smoking history | 23 |
fractional exhaled | 23 |
durch die | 23 |
lymph nodes | 23 |
th responses | 23 |
key role | 23 |
severe rsv | 23 |
childhood wheezing | 23 |
small number | 23 |
atopic patients | 23 |
nasal lavage | 23 |
elderly asthmatic | 23 |
oral corticosteroid | 23 |
included patients | 22 |
host disease | 22 |
older children | 22 |
positive control | 22 |
task force | 22 |
asthma asthma | 22 |
pediatric population | 22 |
reactive protein | 22 |
prick testing | 22 |
health survey | 22 |
well known | 22 |
like receptors | 22 |
eosinophil activation | 22 |
cysteinyl leukotriene | 22 |
written informed | 22 |
human coronavirus | 22 |
endothelial cells | 22 |
significantly less | 22 |
monoclonal antibodies | 22 |
patients undergoing | 22 |
increased susceptibility | 22 |
corticosteroid therapy | 22 |
influenza viruses | 22 |
increased expression | 22 |
allergy clinic | 22 |
confidence interval | 22 |
immune deficiency | 22 |
body weight | 22 |
eosinophil numbers | 22 |
year period | 22 |
late asthmatic | 22 |
mg bid | 22 |
chronic diseases | 22 |
dependent asthma | 22 |
patients using | 22 |
staphylococcus aureus | 22 |
million people | 22 |
reactive oxygen | 22 |
lung microbiome | 22 |
major cause | 22 |
atypical bacteria | 22 |
smoking cessation | 22 |
patient presented | 22 |
children younger | 22 |
oral challenge | 21 |
lymphoid cells | 21 |
skin biopsy | 21 |
forced vital | 21 |
human lung | 21 |
national heart | 21 |
infected cells | 21 |
atopic children | 21 |
latex allergy | 21 |
relatively low | 21 |
currently available | 21 |
total serum | 21 |
aged children | 21 |
specific antibody | 21 |
diagnostic tests | 21 |
genetic factors | 21 |
peripheral eosinophilia | 21 |
streptococcus pneumoniae | 21 |
blood institute | 21 |
fi ndings | 21 |
low levels | 21 |
bronchial reactivity | 21 |
nasal secretions | 21 |
intermittent asthma | 21 |
medical center | 21 |
may increase | 21 |
per day | 21 |
healthy volunteers | 21 |
nasal obstruction | 21 |
productive cough | 21 |
intercellular adhesion | 21 |
results showed | 21 |
study using | 21 |
beneficial effect | 21 |
allograft rejection | 21 |
three months | 21 |
clinical data | 21 |
clinical signs | 21 |
ige sensitization | 21 |
cell surface | 21 |
viral detection | 21 |
lung biopsy | 21 |
muscarinic receptors | 21 |
results patients | 21 |
mucociliary clearance | 21 |
aufgrund der | 21 |
commercially available | 21 |
asthma attack | 21 |
challenge tests | 21 |
genetic variants | 21 |
minute ventilation | 21 |
recurrent respiratory | 21 |
asthmatic response | 21 |
tissue damage | 21 |
cell function | 21 |
von pge | 21 |
oral antibiotics | 21 |
allergic disorders | 21 |
hospitalized patients | 21 |
exclusion criteria | 21 |
asthma triggers | 21 |
small airways | 20 |
study also | 20 |
high resolution | 20 |
extracellular traps | 20 |
otherwise healthy | 20 |
may affect | 20 |
similar results | 20 |
average age | 20 |
statistical analyses | 20 |
patients underwent | 20 |
positive response | 20 |
diffusing capacity | 20 |
metapneumovirus infection | 20 |
statistical significance | 20 |
airway narrowing | 20 |
also play | 20 |
cigarette smoking | 20 |
data collection | 20 |
prevalence rates | 20 |
methods data | 20 |
pulmonary vascular | 20 |
computed tomography | 20 |
parainfluenza viruses | 20 |
von il | 20 |
greater risk | 20 |
study period | 20 |
may reflect | 20 |
protein kinase | 20 |
asthma subjects | 20 |
case reports | 20 |
will also | 20 |
global strategy | 20 |
infectious agents | 20 |
lung injury | 20 |
asthma using | 20 |
signifi cantly | 20 |
related quality | 20 |
associated asthma | 20 |
subcutaneous immunotherapy | 20 |
preliminary data | 20 |
study will | 20 |
symptom control | 20 |
blind placebo | 20 |
life questionnaire | 20 |
type ii | 20 |
response rate | 20 |
significant association | 20 |
pollen counts | 20 |
mit einem | 20 |
high fat | 20 |
infl ammation | 20 |
skin lesions | 20 |
patient outcomes | 20 |
molecular mechanisms | 20 |
neutrophilic asthma | 20 |
age children | 20 |
aumento da | 20 |
airway eosinophils | 20 |
function impairment | 20 |
bronchopulmonary aspergillosis | 20 |
study design | 20 |
flow rate | 20 |
poor control | 20 |
may provide | 20 |
positive airway | 20 |
emphysema severity | 20 |
mouse models | 20 |
oxygen species | 20 |
der allergischen | 20 |
allergy testing | 20 |
months prior | 20 |
school age | 20 |
trigger asthma | 20 |
type iii | 19 |
airway lumen | 19 |
drug allergies | 19 |
pleural effusions | 19 |
ventilation rate | 19 |
eosinophilic gastroenteritis | 19 |
human bronchial | 19 |
differentially expressed | 19 |
chest pain | 19 |
data indicate | 19 |
gina guidelines | 19 |
dose response | 19 |
two weeks | 19 |
oral food | 19 |
positive results | 19 |
dass die | 19 |
dose ics | 19 |
muscle mass | 19 |
host cell | 19 |
wide association | 19 |
induced exacerbations | 19 |
patch tests | 19 |
children without | 19 |
reference equations | 19 |
british thoracic | 19 |
old boy | 19 |
anaphylactic reactions | 19 |
maternal smoking | 19 |
antibiotic therapy | 19 |
studies using | 19 |
arterial blood | 19 |
cat dander | 19 |
der atemwege | 19 |
treat asthma | 19 |
healthy control | 19 |
coronavirus disease | 19 |
receptor expression | 19 |
pulmonary arterial | 19 |
less common | 19 |
dose inhaler | 19 |
control questionnaire | 19 |
normal range | 19 |
current study | 19 |
environmental control | 19 |
neutrophilic airway | 19 |
cell death | 19 |
reference values | 19 |
significant role | 19 |
amino acids | 19 |
month follow | 19 |
intranasal steroids | 19 |
predictive value | 19 |
carbon monoxide | 19 |
control cells | 19 |
physical exam | 19 |
fungal spores | 19 |
medical care | 19 |
randomized clinical | 19 |
city children | 19 |
three years | 19 |
milk protein | 19 |
treatment options | 19 |
higher incidence | 19 |
acute bronchiolitis | 19 |
years ago | 19 |
odds ratios | 19 |
organic compounds | 19 |
well established | 19 |
allergy symptoms | 19 |
significant reductions | 19 |
oral prednisolone | 19 |
acupuncture treatment | 19 |
allergy clin | 19 |
closely related | 19 |
rhinitis patients | 19 |
health status | 18 |
two studies | 18 |
developed countries | 18 |
serum tryptase | 18 |
mild ea | 18 |
younger age | 18 |
nos primeiros | 18 |
autoimmune disease | 18 |
nasal blockage | 18 |
th cell | 18 |
higher doses | 18 |
macrolide antibiotics | 18 |
asthma respiratory | 18 |
clinical study | 18 |
important risk | 18 |
haemophilus influenzae | 18 |
vor allem | 18 |
cpap therapy | 18 |
asthma associated | 18 |
first case | 18 |
carbon dioxide | 18 |
cytokines il | 18 |
common respiratory | 18 |
retrospective chart | 18 |
patients showed | 18 |
ed visits | 18 |
murine model | 18 |
future studies | 18 |
lung cancers | 18 |
environmental exposure | 18 |
guinea pig | 18 |
significantly elevated | 18 |
signifi cant | 18 |
middle ear | 18 |
die bildung | 18 |
atopic sensitization | 18 |
study conducted | 18 |
double blind | 18 |
patients suffering | 18 |
chest ct | 18 |
acute attacks | 18 |
also demonstrated | 18 |
nut allergy | 18 |
cardiovascular disease | 18 |
sputum induction | 18 |
stimulating factor | 18 |
elevated serum | 18 |
third trimester | 18 |
often used | 18 |
respiratory events | 18 |
serum specific | 18 |
new york | 18 |
within weeks | 18 |
transcription factor | 18 |
th immune | 18 |
ciliary dyskinesia | 18 |
nasal epithelial | 18 |
total lung | 18 |
asthma quality | 18 |
cell hyperplasia | 18 |
specific antibodies | 18 |
quantitative pcr | 18 |
group compared | 18 |
independent risk | 18 |
individual patient | 18 |
clinical setting | 18 |
pcr assays | 18 |
clinical problems | 18 |
free diet | 18 |
patienten mit | 18 |
atopic asthmatic | 18 |
least months | 18 |
analysis revealed | 18 |
wheezing children | 18 |
may influence | 18 |
inflammatory process | 18 |
eosinophil degranulation | 18 |
gut microbiome | 18 |
adhesion molecules | 18 |
systematic reviews | 18 |
improved asthma | 18 |
da atopia | 18 |
pneumoniae infection | 18 |
asthmatic adults | 18 |
virus detection | 18 |
international recommendations | 18 |
four patients | 17 |
cell volume | 17 |
primary ciliary | 17 |
antibiotic exposure | 17 |
short course | 17 |
nk cells | 17 |
white blood | 17 |
transcription factors | 17 |
asthma compared | 17 |
machine learning | 17 |
oesophageal reflux | 17 |
ige receptor | 17 |
body size | 17 |
significant change | 17 |
increased asthma | 17 |
general practitioners | 17 |
isaac phase | 17 |
within normal | 17 |
department visits | 17 |
respiratory conditions | 17 |
naturally occurring | 17 |
inhalant allergies | 17 |
one third | 17 |
bei kindern | 17 |
upper airways | 17 |
nervous system | 17 |
arterial hypertension | 17 |
nucleic acids | 17 |
bildung von | 17 |
single dose | 17 |
may represent | 17 |
month period | 17 |
tidal volumes | 17 |
study included | 17 |
breast feeding | 17 |
allergy asthma | 17 |
und eine | 17 |
virus replication | 17 |
often associated | 17 |
mean fev | 17 |
deficient mice | 17 |
consensus statement | 17 |
predicted fev | 17 |
school performance | 17 |
predict asthma | 17 |
studies indicate | 17 |
cc genotype | 17 |
first strategy | 17 |
incidence rates | 17 |
observational studies | 17 |
idiopathic eosinophilic | 17 |
genes associated | 17 |
bronchial responsiveness | 17 |
persistent airway | 17 |
pulmonary inflammation | 17 |
five patients | 17 |
clin immunol | 17 |
topical steroids | 17 |
common chronic | 17 |
ethnic differences | 17 |
adverse reaction | 17 |
pulmonary embolism | 17 |
inflammatory cytokine | 17 |
related asthma | 17 |
remains unclear | 17 |
im vergleich | 17 |
two children | 17 |
percentage change | 17 |
progenitor cells | 17 |
every day | 17 |
systemic reactions | 17 |
health problem | 17 |
desensitization protocol | 17 |
gestational age | 17 |
maintenance therapy | 17 |
normal lung | 17 |
basophil activation | 17 |
may modulate | 17 |
sensitized mice | 17 |
oxygen saturation | 17 |
reverse transcription | 17 |
also reported | 17 |
symptom severity | 17 |
high level | 17 |
rheumatoid arthritis | 17 |
hyperactivity disorder | 17 |
cellular senescence | 17 |
eosinophil granule | 17 |
multivariate analysis | 17 |
gas exchange | 17 |
cd high | 17 |
generalized urticaria | 17 |
common causes | 17 |
methods children | 17 |
histamine challenge | 17 |
building materials | 17 |
disease burden | 17 |
autoimmune diseases | 17 |
severe atopic | 17 |
case series | 17 |
chemokine production | 17 |
wide variety | 16 |
ventilation rates | 16 |
allergic contact | 16 |
ets formation | 16 |
total number | 16 |
medical thoracoscopy | 16 |
lg ml | 16 |
positive biopsy | 16 |
clinical immunology | 16 |
antitrypsin deficiency | 16 |
mdi spacer | 16 |
related symptoms | 16 |
sowie die | 16 |
secretory iga | 16 |
early detection | 16 |
also observed | 16 |
following treatment | 16 |
respiratory mechanics | 16 |
oral immunotherapy | 16 |
aktivierung von | 16 |
rahmen der | 16 |
und il | 16 |
enclosure volume | 16 |
first episode | 16 |
new zealand | 16 |
viral load | 16 |
analyzed using | 16 |
national institute | 16 |
unknown whether | 16 |
novel coronavirus | 16 |
epithelial damage | 16 |
usual care | 16 |
action plans | 16 |
disease states | 16 |
airway neutrophils | 16 |
office workers | 16 |
induced allergic | 16 |
tumor cells | 16 |
patients sensitized | 16 |
patient developed | 16 |
sputum cell | 16 |
dynamic hyperinflation | 16 |
outcome measures | 16 |
association studies | 16 |
group showed | 16 |
acid reflux | 16 |
negative skin | 16 |
eosinophilic colitis | 16 |
old man | 16 |
persistent symptoms | 16 |
difficult asthma | 16 |
reproductive factors | 16 |
chronic otitis | 16 |
interstitial pneumonia | 16 |
western blot | 16 |
beneficial effects | 16 |
least two | 16 |
muscle cells | 16 |
longitudinal cohort | 16 |
patients admitted | 16 |
residual capacity | 16 |
inflammatory disease | 16 |
neutrophil extracellular | 16 |
chronic rhinitis | 16 |
bronchodilator reversibility | 16 |
asthma susceptibility | 16 |
gp dstat | 16 |
ige antibody | 16 |
pollen allergic | 16 |
fat meal | 16 |
treg cells | 16 |
analysis showed | 16 |
infl ammatory | 16 |
outpatient visits | 16 |
bosentan therapy | 16 |
asthma foundation | 16 |
possible role | 16 |
poorly understood | 16 |
inhaled allergens | 16 |
respiratory comorbidity | 16 |
wt mice | 16 |
alternative medicine | 16 |
alternative splicing | 16 |
children ages | 16 |
deficit hyperactivity | 16 |
asthmatic airway | 16 |
three patients | 16 |
rna viruses | 16 |
infection may | 16 |
three groups | 16 |
early morning | 16 |
lung infection | 16 |
cow milk | 16 |
increased il | 16 |
effector cells | 16 |
provocation tests | 16 |
early diagnosis | 16 |
remains controversial | 16 |
hypersensitivity pneumonitis | 16 |
human asthma | 16 |
os estudos | 16 |
mandibular enclosure | 16 |
rescue medication | 16 |
resposta imune | 16 |
reversible airway | 16 |
inverse correlation | 16 |
functional residual | 16 |
different types | 16 |
pulmonary blood | 16 |
severe symptoms | 16 |
challenged mice | 16 |
egg allergy | 16 |
single infections | 16 |
term outcomes | 16 |
study demonstrated | 16 |
respiratory syndrome | 16 |
aqol scores | 16 |
isaac questionnaire | 16 |
vitro studies | 16 |
persistent wheezing | 16 |
pollen exposure | 16 |
mature dcs | 16 |
adaptive immunity | 16 |
european countries | 16 |
patients hospitalized | 16 |
induced anaphylaxis | 16 |
patients referred | 16 |
longitudinal studies | 16 |
three different | 16 |
national institutes | 16 |
vlcd program | 16 |
critical role | 16 |
medical research | 16 |
higher among | 16 |
bacterial pathogens | 15 |
care utilization | 15 |
function test | 15 |
days later | 15 |
nutrition examination | 15 |
perinatal outcomes | 15 |
rhinovirus colds | 15 |
child health | 15 |
also increased | 15 |
healthy infants | 15 |
written asthma | 15 |
later childhood | 15 |
airway reactivity | 15 |
alternaria alternata | 15 |
ocular symptoms | 15 |
perennial allergic | 15 |
copd exacerbations | 15 |
steroid treatment | 15 |
older asthmatic | 15 |
mite allergens | 15 |
cold air | 15 |
study shows | 15 |
first two | 15 |
several different | 15 |
asthma research | 15 |
goblet cells | 15 |
single nucleotide | 15 |
cytokine profiles | 15 |
mucus production | 15 |
asthma will | 15 |
older patients | 15 |
factor receptor | 15 |
significant changes | 15 |
continuous positive | 15 |
daily activities | 15 |
dendritic cell | 15 |
antibiotic treatment | 15 |
less severe | 15 |
newly discovered | 15 |
western blotting | 15 |
cat exposure | 15 |
allergy syndrome | 15 |
systemic symptoms | 15 |
healthy smokers | 15 |
lung health | 15 |
clinical severity | 15 |
chlamydophila pneumoniae | 15 |
bronchial brushing | 15 |
epidermal growth | 15 |
fungal allergens | 15 |
six years | 15 |
serum il | 15 |
chronic infection | 15 |
des asthma | 15 |
human disease | 15 |
may induce | 15 |
indoor environments | 15 |
data will | 15 |
sich die | 15 |
asthma incidence | 15 |
asthma related | 15 |
univariate analysis | 15 |
infection control | 15 |
total score | 15 |
immunosorbent assay | 15 |
ecp levels | 15 |
diseases including | 15 |
recurrent wheeze | 15 |
runny nose | 15 |
healthy adults | 15 |
ats ers | 15 |
inflammatory markers | 15 |
developing countries | 15 |
protein expression | 15 |
oral allergy | 15 |
treatment strategies | 15 |
nasal symptom | 15 |
respiratory epithelial | 15 |
standard treatment | 15 |
stranded rna | 15 |
bacterial species | 15 |
whole blood | 15 |
lung transplant | 15 |
cell adhesion | 15 |
positive spt | 15 |
vital signs | 15 |
beclomethasone dipropionate | 15 |
decreased lung | 15 |
evaluation revealed | 15 |
past medical | 15 |
per month | 15 |
wheezing rhinovirus | 15 |
preterm delivery | 15 |
roc curve | 15 |
complete resolution | 15 |
hospital stay | 15 |
common colds | 15 |
icu admission | 15 |
patients completed | 15 |
gastrointestinal symptoms | 15 |
gabe von | 15 |
food sensitization | 15 |
positive test | 15 |
inflammatory effects | 15 |
igg antibodies | 15 |
lung capacity | 15 |
asthma mortality | 15 |
disease progression | 15 |
multiple logistic | 15 |
every weeks | 15 |
authors declare | 15 |
antibody responses | 15 |
mechanisms underlying | 15 |
auch bei | 15 |
patients presented | 15 |
associated wheezing | 15 |
therapy may | 15 |
clinical research | 15 |
receptor gene | 14 |
und den | 14 |
potential risk | 14 |
ist es | 14 |
log feno | 14 |
der lunge | 14 |
examination survey | 14 |
may include | 14 |
methods patients | 14 |
per patient | 14 |
lung development | 14 |
serum samples | 14 |
stage iii | 14 |
premature infants | 14 |
among adults | 14 |
primary endpoint | 14 |
scfos lcfos | 14 |
blood cultures | 14 |
asthma immunology | 14 |
human rhinoviruses | 14 |
detection rates | 14 |
lower limit | 14 |
patient education | 14 |
liver disease | 14 |
activated eosinophils | 14 |
incidence rate | 14 |
macrophage colony | 14 |
asthma cases | 14 |
allergen components | 14 |
lymph node | 14 |
von der | 14 |
barrier integrity | 14 |
respiratory epithelium | 14 |
auch eine | 14 |
effector functions | 14 |
calculated using | 14 |
small airway | 14 |
african american | 14 |
polyp tissue | 14 |
also shown | 14 |
serum concentrations | 14 |
blood tests | 14 |
incident asthma | 14 |
bronchial obstruction | 14 |
better understand | 14 |
mexico city | 14 |
cam therapies | 14 |
von eosinophilen | 14 |
medical records | 14 |
mg qd | 14 |
disease characterized | 14 |
asthma prevention | 14 |
two months | 14 |
early exposure | 14 |
patient reported | 14 |
mean score | 14 |
animal model | 14 |
likely due | 14 |
increased numbers | 14 |
respiratory inflammation | 14 |
supplemental oxygen | 14 |
mg daily | 14 |
using multiple | 14 |
breast milk | 14 |
allergic inflammatory | 14 |
viral rna | 14 |
low risk | 14 |
health services | 14 |
pollen allergens | 14 |
reversibility testing | 14 |
age asthma | 14 |
may improve | 14 |
eosinophil levels | 14 |
current smokers | 14 |
case illustrates | 14 |
term follow | 14 |
laboratory tests | 14 |
expression levels | 14 |
gi tract | 14 |
protective effects | 14 |
outpatient clinic | 14 |
placental abruption | 14 |
children whose | 14 |
patients will | 14 |
inflammatory bowel | 14 |
five years | 14 |
high concentrations | 14 |
mechanisms involved | 14 |
drug reaction | 14 |
using spss | 14 |
life exposure | 14 |
clinical outcome | 14 |
milk proteins | 14 |
atopic subjects | 14 |
one second | 14 |
hmpv infection | 14 |
patients whose | 14 |
passive smoking | 14 |
treated mice | 14 |
asthmatic patient | 14 |
higher rate | 14 |
may indicate | 14 |
well controlled | 14 |
serum immunoglobulin | 14 |
human subjects | 14 |
asthma assessment | 14 |
will help | 14 |
polyunsaturated fatty | 14 |
rsv infections | 14 |
cancer patients | 14 |
fish oil | 14 |
variable airflow | 14 |
cluster analysis | 14 |
three times | 14 |
epidemiological study | 14 |
ragweed pollen | 14 |
three days | 14 |
specific immunoglobulin | 14 |
comorbid conditions | 14 |
steroid therapy | 14 |
receptor agonists | 14 |
vascular endothelial | 14 |
much lower | 14 |
bronchial challenge | 14 |
drug reactions | 14 |
animal studies | 14 |
international guidelines | 14 |
two thirds | 14 |
cytokine il | 14 |
aus der | 14 |
identifi ed | 14 |
au ml | 14 |
children may | 14 |
panel report | 14 |
one hundred | 14 |
life predict | 14 |
clinical benefit | 14 |
studies show | 14 |
beim asthma | 14 |
common allergens | 14 |
high rhinovirus | 14 |
practice guidelines | 14 |
maintenance treatment | 14 |
association study | 14 |
je nach | 14 |
motif chemokine | 14 |
affected horses | 14 |
may benefit | 14 |
oral mucosa | 14 |
children less | 14 |
endothelial growth | 13 |
ige synthesis | 13 |
major allergens | 13 |
nasal swab | 13 |
recurrent episodes | 13 |
nasal discharge | 13 |
poor metabolizers | 13 |
several factors | 13 |
higher frequency | 13 |
hdm slit | 13 |
maintenance phase | 13 |
blood count | 13 |
cell lung | 13 |
written action | 13 |
gas transfer | 13 |
placebo controlled | 13 |
weeks gestation | 13 |
ist ein | 13 |
infections may | 13 |
lung damage | 13 |
ct scans | 13 |
pleural effusion | 13 |
bronchial hyper | 13 |
induced lung | 13 |
genetic studies | 13 |
past years | 13 |
positive controls | 13 |
less clear | 13 |
many cases | 13 |
among people | 13 |
control asthma | 13 |
assessed using | 13 |
routine clinical | 13 |
line treatment | 13 |
severe bronchiolitis | 13 |
human influenza | 13 |
underlying mechanisms | 13 |
respiratory study | 13 |
intervention strategy | 13 |
mesothelin levels | 13 |
regression model | 13 |
reduces asthma | 13 |
secondary prevention | 13 |
fi brosis | 13 |
crs patients | 13 |
von mutius | 13 |
related air | 13 |
respiratory medicine | 13 |
type response | 13 |
elderly asthmatics | 13 |
line therapy | 13 |
reduce asthma | 13 |
eosinophilic airway | 13 |
also identified | 13 |
skin diseases | 13 |
winter months | 13 |
parental history | 13 |
central role | 13 |
glutathione peroxidase | 13 |
independent predictors | 13 |
day care | 13 |
serum level | 13 |
die allergische | 13 |
comparative study | 13 |
hiv infection | 13 |
also significantly | 13 |
acute episode | 13 |
negative control | 13 |
dry cough | 13 |
symptoms related | 13 |
time period | 13 |
four weeks | 13 |
may explain | 13 |
respiratory allergy | 13 |
reverse transcribed | 13 |
methacholine challenge | 13 |
common food | 13 |
lipid mediators | 13 |
new therapeutic | 13 |
relatively small | 13 |
elderly persons | 13 |
clinical asthma | 13 |
cytokine expression | 13 |
medical conditions | 13 |
soluble factors | 13 |
viral pathogens | 13 |
obstruktiven atemwegserkrankungen | 13 |
bacterial products | 13 |
im gegensatz | 13 |
ten patients | 13 |
children born | 13 |
ground glass | 13 |
asthma monitoring | 13 |
cytokine responses | 13 |
studies investigating | 13 |
durch eine | 13 |
symptoms among | 13 |
study evaluating | 13 |
new orleans | 13 |
metered dose | 13 |
function parameters | 13 |
reduced expression | 13 |
attention deficit | 13 |
months later | 13 |
children using | 13 |
muscle hypertrophy | 13 |
serum vitamin | 13 |
fungal species | 13 |
obese patients | 13 |
nasopharyngeal aspirate | 13 |
fl uid | 13 |
infection induces | 13 |
physician visits | 13 |
normal values | 13 |
nasal allergy | 13 |
urinary antigen | 13 |
cell numbers | 13 |
obstruction group | 13 |
two hours | 13 |
mucus secretion | 13 |
severe forms | 13 |
controller medications | 13 |
advanced lung | 13 |
corticosteroid use | 13 |
myocardial infarction | 13 |
study reported | 13 |
maternal asthma | 13 |
wheezing disorders | 13 |
ist der | 13 |
molecular weight | 13 |
asthma und | 13 |
hae patients | 13 |
exacerbation rate | 13 |
indoor environmental | 13 |
inhaled allergen | 13 |
stem cell | 13 |
reduced risk | 13 |
i interferon | 13 |
environmental allergens | 13 |
childhood infections | 13 |
organ involvement | 13 |
antimicrobial peptides | 13 |
children respiratory | 13 |
people aged | 13 |
asthma health | 13 |
wall thickness | 13 |
using flow | 13 |
objective measures | 13 |
die die | 13 |
allergic responses | 13 |
genetic predisposition | 13 |
daily dose | 13 |
type cytokines | 13 |
severe ad | 13 |
injectable epinephrine | 13 |
patients presenting | 13 |
mice received | 13 |
disease remains | 13 |
rescue intervention | 13 |
clinical utility | 13 |
bleomycin treated | 13 |
newly diagnosed | 13 |
causal relationship | 13 |
bronchial wall | 13 |
one month | 13 |
sensitized patients | 13 |
cell metaplasia | 13 |
symptom onset | 13 |
expert panel | 13 |
environment interaction | 13 |
economic burden | 13 |
increased production | 13 |
asthmatic symptoms | 13 |
developed asthma | 13 |
antiviral therapy | 13 |
elimination diet | 13 |
increased incidence | 13 |
derived neurotoxin | 13 |
lymphoid tissue | 13 |
children treated | 13 |
nucleic acid | 12 |
european respiratory | 12 |
rv replication | 12 |
exacerbation rates | 12 |
cell lysis | 12 |
may prove | 12 |
culture positive | 12 |
respiratory morbidity | 12 |
avian influenza | 12 |
von cox | 12 |
clinical evaluation | 12 |
assess whether | 12 |
first hospital | 12 |
conductive ventilation | 12 |
may become | 12 |
increased significantly | 12 |
systemic corticosteroid | 12 |
mediated immunity | 12 |
cytokine release | 12 |
income countries | 12 |
reg cd | 12 |
dog dander | 12 |
total aqol | 12 |
periostin levels | 12 |
many years | 12 |
background asthma | 12 |
um die | 12 |
induced eosinophil | 12 |
nasal swabs | 12 |
vast majority | 12 |
tlr agonists | 12 |
pack year | 12 |
allergy unit | 12 |
nach der | 12 |
obstruktiven bronchitiden | 12 |
human eosinophil | 12 |
appropriately sized | 12 |
routine cta | 12 |
severe equine | 12 |
mit dem | 12 |
south australia | 12 |
cytokine chemokine | 12 |
limited data | 12 |
sinonasal tissue | 12 |
local reactions | 12 |
endotracheal intubation | 12 |
weight gain | 12 |
disease activity | 12 |
inhaled budesonide | 12 |
urban pm | 12 |
arachidonic acid | 12 |
mg dose | 12 |
exercise group | 12 |
without treatment | 12 |
cell granzyme | 12 |
para os | 12 |
among asthmatic | 12 |
oral provocation | 12 |
venous blood | 12 |
physical activity | 12 |
mucosal inflammation | 12 |
primary immunodeficiency | 12 |
die il | 12 |
allergischen erkrankungen | 12 |
recently published | 12 |
patients allergic | 12 |
broad spectrum | 12 |
must also | 12 |
antiviral activity | 12 |
airway responses | 12 |
atopic individuals | 12 |
stable copd | 12 |
first study | 12 |
care providers | 12 |
impulse oscillometry | 12 |
diagnosed artpah | 12 |
poor quality | 12 |
stent thrombosis | 12 |
days following | 12 |
studies reported | 12 |
stat signalling | 12 |
vergleich zu | 12 |
complete blood | 12 |
evaluated using | 12 |
nitrogen oxides | 12 |
difficulty breathing | 12 |
reticular pattern | 12 |
specific iga | 12 |
binding capacity | 12 |
events hour | 12 |
sulfur dioxide | 12 |
dose inhaled | 12 |
whole genome | 12 |
expression von | 12 |
hedland pm | 12 |
lung windows | 12 |
respiratory disorders | 12 |
pneumonia severity | 12 |
inhaled fluticasone | 12 |
test reactivity | 12 |
cell degranulation | 12 |
study drug | 12 |
controlled studies | 12 |
case control | 12 |
second strategy | 12 |
chronic exposure | 12 |
adult population | 12 |
asthma genetics | 12 |
university first | 12 |
well studied | 12 |
patient days | 12 |
significant associations | 12 |
acute graft | 12 |
sized donor | 12 |
gene cd | 12 |
frequently used | 12 |
airway mucosa | 12 |
excluded due | 12 |
may allow | 12 |
pitjantjatjara lands | 12 |
bronchiolitis obliterans | 12 |
respiratory muscle | 12 |
allergic sensitisation | 12 |
progressive dyspnoea | 12 |
asm tone | 12 |
pleural plaques | 12 |
linear regression | 12 |
left ventricular | 12 |
intradermal skin | 12 |
normal limits | 12 |
ffm hydration | 12 |
fatal asthma | 12 |
lower risk | 12 |
longer duration | 12 |
vascular permeability | 12 |
may impact | 12 |
weeks smoking | 12 |
prevent exacerbations | 12 |
wheat flour | 12 |
presenting cells | 12 |
family size | 12 |
gps recruited | 12 |
asthmatic reactions | 12 |
results data | 12 |
training mwd | 12 |
intradermal testing | 12 |
lung inflation | 12 |
receiver operator | 12 |
lymphocyte count | 12 |
acute lower | 12 |
linked immunosorbent | 12 |
children presenting | 12 |
cig smoke | 12 |
traditional chinese | 12 |
study comparing | 12 |
independently associated | 12 |
male patient | 12 |
cbt intervention | 12 |
much less | 12 |
cancer cases | 12 |
severe asthmatics | 12 |
dietary intake | 12 |
baseline fev | 12 |
torres strait | 12 |
lower lung | 12 |
status asthmaticus | 12 |
mice exposed | 12 |
peking university | 12 |
primeiros anos | 12 |
cd gene | 12 |
subsequent childhood | 12 |
underlying cause | 12 |
total cost | 12 |
based studies | 12 |
th profile | 12 |
persistent disease | 12 |
cell receptor | 12 |
significant increases | 12 |
laboratory data | 12 |
obstructive airway | 12 |
aspirin sensitivity | 12 |
positive tbb | 12 |
lung tissues | 12 |
infectious asthma | 12 |
protective role | 12 |
younger children | 12 |
ebc nox | 12 |
natural course | 12 |
morning peak | 12 |
fetal outcomes | 12 |
early studies | 12 |
methods subjects | 12 |
ulcerative colitis | 12 |
right diaphragm | 12 |
resolution computed | 12 |
old caucasian | 12 |
late preterm | 12 |
apnea syndrome | 12 |
cbt group | 12 |
tumour antigen | 12 |
global lung | 12 |
mucus hypersecretion | 12 |
influenza infection | 12 |
study aims | 12 |
plasmacytoid dendritic | 12 |
following training | 12 |
pollen grains | 12 |
predictive normal | 12 |
cells via | 12 |
congenital malformations | 12 |
cypress pollen | 12 |
olive tree | 12 |
treatment protocol | 12 |
levels may | 12 |
mediator release | 12 |
asthma onset | 12 |
peanut allergens | 12 |
caval shunt | 12 |
care workers | 12 |
nuclear export | 12 |
pollen extract | 12 |
test result | 12 |
probably due | 12 |
protease activity | 12 |
via mdi | 12 |
varying degrees | 12 |
cell type | 12 |
results show | 12 |
splice variant | 12 |
phagocytic function | 12 |
becoming increasingly | 12 |
wheezing illnesses | 12 |
matrix metalloproteinase | 12 |
high rate | 12 |
patient population | 12 |
tract disease | 12 |
strategy recruited | 12 |
experimental studies | 12 |
pattern recognition | 12 |
poor performance | 12 |
human respiratory | 12 |
viral coinfection | 12 |
neutrophil elastase | 12 |
serum albumin | 12 |
laboratory findings | 12 |
interview survey | 12 |
activated mast | 12 |
mean level | 12 |
cancer risk | 12 |
class ii | 12 |
der akuten | 12 |
tracheal mucus | 12 |
including il | 12 |
muscarinic receptor | 12 |
respiratory samples | 12 |
patient demographics | 12 |
quality control | 12 |
ultrasonic flow | 12 |
well documented | 12 |
preliminary results | 12 |
dairy products | 12 |
cells ml | 12 |
lung parenchyma | 12 |
molar mass | 12 |
antiviral responses | 12 |
significant effect | 12 |
acting bronchodilator | 12 |
related airway | 12 |
clinical effectiveness | 12 |
based cohort | 12 |
unclear whether | 11 |
mm hg | 11 |
immune complexes | 11 |
asthma symptom | 11 |
skin symptoms | 11 |
increasing doses | 11 |
common variable | 11 |
per se | 11 |
oral antihistamines | 11 |
early intervention | 11 |
skin tested | 11 |
phase three | 11 |
patient showed | 11 |
severe reactions | 11 |
management strategies | 11 |
sind die | 11 |
asthma include | 11 |
increased likelihood | 11 |
may act | 11 |
clinical findings | 11 |
infancy predict | 11 |
spontaneous urticaria | 11 |
data support | 11 |
infantile colic | 11 |
flow meter | 11 |
pulmonary edema | 11 |
pediatric subjects | 11 |
single gene | 11 |
studies will | 11 |
present within | 11 |
antiviral response | 11 |
exacerbate asthma | 11 |
respiratory secretions | 11 |
population sample | 11 |
risk asthmatics | 11 |
matched controls | 11 |
total body | 11 |
study suggest | 11 |
patients following | 11 |
medical treatment | 11 |
host defense | 11 |
disease may | 11 |
children living | 11 |
gel electrophoresis | 11 |
wound healing | 11 |
nan title | 11 |
asthma affects | 11 |
homeopathic remedies | 11 |
high incidence | 11 |
cytokine levels | 11 |
ige igg | 11 |
crossover study | 11 |
zu einem | 11 |
infectious disease | 11 |
moderate severe | 11 |
lamina propria | 11 |
renal failure | 11 |
minimum database | 11 |
also affect | 11 |
tumor growth | 11 |
effects associated | 11 |
exacerbated respiratory | 11 |
numerous studies | 11 |
dermatophagoides farinae | 11 |
ml vs | 11 |
zu den | 11 |
murine models | 11 |
genetic basis | 11 |
strong th | 11 |
asthmatic bronchial | 11 |
prevent asthma | 11 |
findings indicate | 11 |
recombinant protein | 11 |
patients included | 11 |
muscle tissue | 11 |
indoor allergens | 11 |
age months | 11 |
antibody response | 11 |
airway disorders | 11 |
specific th | 11 |
wirkung der | 11 |
immune diseases | 11 |
study asthma | 11 |
der obstruktiven | 11 |
clinical disease | 11 |
reduced asthma | 11 |
significant adverse | 11 |
additional asthma | 11 |
asthma also | 11 |
worsening asthma | 11 |
inflammatory processes | 11 |
clinical samples | 11 |
emergency departments | 11 |
subsequent asthma | 11 |
several weeks | 11 |
resistant asthma | 11 |
immunodeficiency virus | 11 |
retrospective analysis | 11 |
including allergic | 11 |
cat allergens | 11 |
eine rolle | 11 |
acute episodes | 11 |
respiratory society | 11 |
regulatory cells | 11 |
natural colds | 11 |
sleep medicine | 11 |
strong association | 11 |
eight patients | 11 |
negative controls | 11 |
die cox | 11 |
life antibiotic | 11 |
study investigating | 11 |
blood ige | 11 |
authors concluded | 11 |
children infected | 11 |
cell cultures | 11 |
peach tree | 11 |
eine reduzierte | 11 |
bronchial smooth | 11 |
fluticasone salmeterol | 11 |
healthy horses | 11 |
additional studies | 11 |
interquartile range | 11 |
activation test | 11 |
threshold dose | 11 |
also performed | 11 |
stent implantation | 11 |
community respiratory | 11 |
female patient | 11 |
neutrophil infiltration | 11 |
functional significance | 11 |
tissue eosinophils | 11 |
cause airway | 11 |
mucous membrane | 11 |
inflammatory mechanisms | 11 |
urine samples | 11 |
different clinical | 11 |
investigated whether | 11 |
bowel disease | 11 |
ocs use | 11 |
tissue remodeling | 11 |
diabetes mellitus | 11 |
seminal fluid | 11 |
samples taken | 11 |
healthcare professionals | 11 |
lung mechanics | 11 |
nk cell | 11 |
cold virus | 11 |
negative impact | 11 |
late phase | 11 |
secondary outcomes | 11 |
th day | 11 |
observation group | 11 |
fed infants | 11 |
gamma ifn | 11 |
well described | 11 |
matched control | 11 |
six patients | 11 |
low cd | 11 |
inflammation may | 11 |
infected patients | 11 |
conjugate vaccine | 11 |
well understood | 11 |
iga levels | 11 |
fev vc | 11 |
lung fibrosis | 11 |
still unclear | 11 |
modifiable factors | 11 |
across different | 11 |
resolution ct | 11 |
blood cell | 11 |
hr post | 11 |
mean percentage | 11 |
ist eine | 11 |
pleural fl | 11 |
current evidence | 11 |
reflux disorders | 11 |
biopsy revealed | 11 |
old girl | 11 |
th immunity | 11 |
ige response | 11 |
der regel | 11 |
converting enzyme | 11 |
increased use | 11 |
several years | 11 |
twin pairs | 11 |
surfactant protein | 11 |
recovery group | 11 |
fully understood | 11 |
patients diagnosed | 11 |
higher concentrations | 11 |
type inflammation | 11 |
bacterial colonization | 11 |
results demonstrate | 11 |
randomized double | 11 |
term asthma | 11 |
major risk | 11 |
coronary arteries | 11 |
ophthalmic solution | 11 |
lip swelling | 11 |
treatment approaches | 11 |
appropriate management | 11 |
cochrane review | 11 |
made available | 11 |
viral wheeze | 11 |
clinical picture | 11 |
human monocyte | 11 |
studies showing | 11 |
derived growth | 11 |
newly identified | 11 |
sectional studies | 11 |
viruses associated | 11 |
subjects allergic | 11 |
rahmen von | 11 |
immunocap isac | 11 |
single infection | 11 |
sore throat | 11 |
ild patients | 11 |
old white | 11 |
beobachtete man | 11 |
pcn skin | 11 |
drug therapy | 11 |
normal levels | 11 |
milk consumption | 11 |
membrane thickening | 11 |
among older | 11 |
sialic acid | 11 |
allergen specific | 11 |
cam therapy | 11 |
congestive heart | 11 |
north america | 11 |
neuraminidase inhibitors | 11 |
cell populations | 11 |
increasing prevalence | 11 |
oxide levels | 11 |
office visits | 11 |
patients years | 11 |
oral tolerance | 11 |
conventional treatment | 11 |
bone mineral | 11 |
inflammatory properties | 11 |
airways inflammation | 11 |
increased release | 11 |
expiratory airflow | 11 |
mild intermittent | 11 |
predict subsequent | 11 |
immune systems | 11 |
moderate persistent | 11 |
lung fibroblasts | 11 |
bronchial provocation | 11 |
crucial role | 11 |
airway inflammatory | 11 |
seven patients | 11 |
host response | 11 |
low concentrations | 11 |
eine wichtige | 11 |
die wirkung | 11 |
helicobacter pylori | 11 |
ics therapy | 11 |
high degree | 11 |
using immunohistochemistry | 11 |
allergen extracts | 11 |
normal controls | 11 |
positively correlated | 11 |
allergic respiratory | 11 |
early stage | 11 |
gene transcription | 10 |
und des | 10 |
induced il | 10 |
exacerbations per | 10 |
recent data | 10 |
enrolled children | 10 |
may present | 10 |
previously described | 10 |
primeiros tempos | 10 |
limited number | 10 |
mometasone furoate | 10 |
binding lectin | 10 |
four groups | 10 |
asthma study | 10 |
inflammatory th | 10 |
life respiratory | 10 |
prospective longitudinal | 10 |
physical exercise | 10 |
controlled clinical | 10 |
controller therapy | 10 |
culture medium | 10 |
normal epithelial | 10 |
randomly selected | 10 |
activated protein | 10 |
sickle cell | 10 |
respiratory outcomes | 10 |
nasal provocation | 10 |
common aeroallergens | 10 |
previous study | 10 |
hours later | 10 |
increased rate | 10 |
will provide | 10 |
infection compared | 10 |
ers ats | 10 |
study suggests | 10 |
develop asthma | 10 |
atopic family | 10 |
acute phase | 10 |
elisa inhibition | 10 |
allergen skin | 10 |
detected virus | 10 |
major role | 10 |
eosinophil survival | 10 |
related allergic | 10 |
relative risk | 10 |
cytokine response | 10 |
urgent care | 10 |
positive reactions | 10 |
bronchodilator therapy | 10 |
thrombin generation | 10 |
study evaluated | 10 |
tryptase levels | 10 |
ocular itching | 10 |
tissue repair | 10 |
report describes | 10 |
may involve | 10 |
allergic individuals | 10 |
eoe patients | 10 |
tracheal wash | 10 |
symptoms may | 10 |
mediated cytotoxicity | 10 |
blood levels | 10 |
adversely affect | 10 |
food allergen | 10 |
immunoglobulin levels | 10 |
mit den | 10 |
perfil th | 10 |
questionnaire survey | 10 |
prevention program | 10 |
molecular mass | 10 |
also examined | 10 |
childhood pneumonia | 10 |
severe combined | 10 |
disease process | 10 |
tiotropium bromide | 10 |
sedating antihistamines | 10 |
also may | 10 |
plasma cells | 10 |
auch der | 10 |
ventilation systems | 10 |